IMMUWHY
A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care (IMMUWHY)
II
interventionell
National
Durvalumab versus
Tremelimumab + Durvalumab
Status: In Rekrutierung
Zeitraum
2020
2024
Zentren
20
9
Auf Anfrage
Patienten
50
24
04.04.2024
Klinische Settings
1st line, 2nd line
palliativ
Beteiligte
AIO-Arbeitsgruppen
Sponsor
Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
Förderer
AstraZeneca
Identifier
AIO-HEP-0119/ass
IMMUWHY
2018-004778-81
Kontakt
Leitung
Prof. Dr. med. Arndt Vogel
Ansprechpartner*in
Dr. Dörthe Vortmeyer
Telefon +49 69 7601-4196
E-Mail vortmeyer.doerthe@ikf-khnw.de